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 Th e paper by Merchant  et al. 1 in this issue 
of  Kidney International is an important 
approach to the issue of hyporesponsive-
ness to erythropoiesis-stimulating agents 
(ESAs) when obvious causes are not 
apparent. Th eir approach is identifi cation 
of biomarkers of ESA response in hemo-
dialysis patients, using peptidomic 
 ana lyses of patient sera and mass spec-
trometry. Th e fi ndings of these experi-
ments are interesting and novel, marking 
the  discovery of serum peptides originat-
ing from the oncostatin M receptor and 
cysteine / histidine-rich 1 proteins as can-
didate biomarkers of poor and good 
response to ESA therapy, respectively. 
Although the study was restricted to the 
use of the fi rst-generation ESA epoetin 
alfa, the approach is likely to extend to 
similar-class  biosimilar and longer-acting 
agents and may extend to newly develop-
ing hypoxia-inducible  factor (HIF)-
 acting agents. 
 It must be stressed that introduction of 
ESAs produced substantial reductions in 
the blood transfusion requirements of 
patients suff ering from chronic kidney 
disease (CKD). Th us, hyporesponsiveness 
to ESAs is an important issue in the suc-
cessful management of anemia in patients 
with CKD, and hyporesponsiveness may 
be transient or persistent. Th e two most 
common reasons why patients become 
relatively unresponsive to ESA therapy are 
the development of true iron defi ciency 
(which occurs less frequently now as a 
result of aggressive iron supplementation) 
and the onset of an infl ammatory state 
that impairs the response to ESAs. 2 Th ese 
elements are not unique to patients with 
CKD, but patients with CKD, especially 
those on hemodialysis, may be at an 
increased risk due to infl ammation and 
may have previously been subject to 
decreases in hemoglobin (Hb) and hema-
tocrit and consequent increased ESA dose 
requirements. Importantly, the bone 
marrow progenitor cells that are the most 
sensitive to the various cytokines pro-
duced during infl ammation are the eryth-
roid colony-forming units, as opposed to 
the more primitive erythroid burst-form-
ing units. Th e eff ects of some cytokines, 
such as tumor necrosis factor-  , are not 
overcome by a simple increase in the ESA 
concentrations. 
 Intercurrent infection is almost 
certainly the most common reason why 
patients become temporarily (and revers-
ibly) ESA-resistant. ESA responsiveness 
improves when iron defi ciency (or another 
substrate deficiency) or an underlying 
inflammatory condition is treated. 
Response to iron repletion is relatively 
rapid, and very high Hb levels may obtain 
when ESA doses are not down-titrated 
rapidly. Aft er therapy and control of the 
infl ammatory state, it may take weeks to 
realize full responsiveness and several 
months to attain the desired Hb level. 
Reduction in cytokines, through prompt 
treatment of the underlying disorder, 
invariably engenders a much lower ESA 
dose to achieve the target Hb level. 
 Entities that induce chronic ESA 
hyporesponsiveness that can be partially 
overcome by escalating ESA doses include 
myelofi brosis, malignancy, thalassemia, 
sickle-cell disease, and untreated HIV /
 AIDS. Th e presence of these is usually 
known at the time of anemia treatment 
and ESA dose escalation. More recently 
described is pure red-cell aplasia, which 
results from antibodies directed against 
endogenous and exogenous epoetins. 
Until recently, the only available therapies 
were immunosuppression and / or red 
blood cell transfusions, but now adminis-
tration of an erythromimetic peptide 
without homology to erythropoietin has 
been salutary. 
 It has been recognized since the initial 
introduction of the fi rst ESA, epoetin alfa, 
in 1986 – 1987 that individual dialysis-
dependent CKD patients vary signifi cantly 
in the dose of ESA required to correct 
their anemia. Many studies have shown 
that the target mean Hb achieved is pro-
portional to the dose given, at the popula-
tion level. Data from the Clinical 
Performance Measures Project of the 
Centers for Medicare and Medicaid Serv-
ices clearly demonstrate parallel increases 
of Hb levels and epoetin doses from 1995 
to 2004. As the dose increased from 175 
U / kg to 275 U / kg weekly, the mean Hb 
increased from 10.5 to 11.7 g / dl, while the 
ESA dose of people who achieved an Hb 
level of 11 – 13 g / dl varied more than 
50-fold. Th e pressure to attain higher Hb 
levels from 1997 to 2006 evolved in part 
from perceived improvements in quality 
of life and persistent observational fi nd-
ings of lower mortality and hospitalization 
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at higher as compared with lower achieved 
Hb values in hemodialysis patients. 
 Th is upward trend in Hb levels ended 
abruptly in 2006 with the publication of 
the Cardiovascular Risk Reduction by 
Early Anemia Treatment with Epoetin 
Beta (CREATE) and Correction of Hemo-
globin and Outcomes in Renal Insuffi  -
ciency (CHOIR) trials in non-dialysis 
CKD patients, and a meta-analysis in 
dialysis-dependent and non-dialysis CKD 
patients that targeted an entire population 
to a Hb level of at least 13 g / dl produced 
harm rather than further benefit, 3 
confi rming the original observation of the 
Normal Hematocrit Trial (NHCT). 4 Th ese 
recent clinical trials included dialysis-
dependent 5 and non-dialysis CKD 
patients 6 treated with ESAs to Hb targets 
greater than the range labeled by the US 
Food and Drug Administration, 10 – 12 
g / dl, and raised safety concerns. Product 
labeling was subsequently revised to 
include a black-box warning, which, in 
the United States, led to a reduction from 
60 % to 46 % in the proportion of non-
dialysis CKD patients receiving an ESA, a 
25 % reduction in ESA dose and a decrease 
from 11.5 g / dl to 10.6 g / dl in mean Hb 
achieved. 7 Notably, this trend had begun 
before publication of the CHOIR trial in 
2007 and accelerated thereaft er. US Renal 
Data System data depict a similar, less dra-
matic decrease in mean Hb (of 0.5 g / dl) 
and in ESA dose in dialysis-dependent 
CKD patients (A.J. Collins, personal com-
munication). 
 The paradox of observational trials 
demonstrating benefi t and randomized 
controlled trials revealing harm at higher 
achieved Hb levels may arise from the 
administration of futile higher ESA doses 
to relatively ESA-resistant CKD patients. 
In an analysis of data from 7400 randomly 
selected patients representing the US 
hemodialysis population in 2005 (the 
Clinical Performance Measures Project), 
we found that 15 % of hyporesponsive 
patients (defi ned as   > 150 U / kg of epoetin 
alfa administered three times weekly) 
consumed 52.5 % of the total ESAs pre-
scribed ( Figure 1 ). In many, ESA dose 
escalations did not alter Hb over a 
3-month period. Consequently, we pro-
posed a hypothesis based on  post hoc 
analyses of the NHCT 8 and the CHOIR 
trial: 9 failure to achieve high Hb levels, 
rather than the level itself, may have been 
responsible for the poor outcomes. Simi-
larly, the Trial to Reduce Cardiovascular 
Events With Aranesp Th erapy (TREAT) 
 post hoc analysis by Solomon and col-
leagues 10 correlated an initial suboptimal 
response with enhanced risk for a cardio-
vascular composite event (hazard ratio 
1.31) and for all-cause death (hazard ratio 
1.41). The poor outcomes may have 
resulted from toxicities related to high-
dose ESAs, patient-level factors underpin-
ning ESA hyporesponsiveness, or a 
combination of both. Th e CREATE trial 
did not demonstrate any harm from the 
greater targeted Hb, but the median 
epoetin doses were considerably lower 
(5000 IU / wk and 2000 IU / wk in the nor-
mal and subnormal Hb groups, respec-
tively) than those in the NHCT and 
CHOIR studies, suggesting that a high Hb 
target  per se may not have been directly 
responsible for worse outcomes when 
high doses of ESAs were avoided. 
 Currently, there is reasonable evidence 
to indicate possibly more harm than ben-
efi t from targeting higher Hb levels with 
ESA therapy, especially in hyporesponsive 
people. Clinical trials to date have focused 
primarily on Hb targets and have 
neglected ESA dosing and other patient-
related factors, including concurrent ill-
ness, infl ammation, and iron therapy. We 
contend that a two-by-two factorial trial 
of the hyporesponsive patient should be 
conducted. Eligible patients would be ran-
domized to a higher or lower ESA dose and 
a higher or lower Hb target within the cur-
rently recommended range, 10 – 12 g / dl. 
 Unfortunately, until the study by 
Merchant  et al. , 1 there has been disagree-
ment on a uniform defi nition of hypore-
sponsiveness. Assigning responsiveness 
from a snapshot of data over 1 or 2 months 
could easily produce misclassifi cation, 
particularly in ESA-naive patients. Tran-
sient cycling within a 6-month period is 
well established, and during the cycle, Hb 
may vary by 2 – 4 g / dl while ESA doses are 
varied monthly (or more frequently) in an 
attempt to avoid Hb levels outside the 
range, usually with a pronounced lag 
phase between the ESA change and the 
resulting Hb level. 
 A major strength of the study by 
Merchant  et al. 1 is that an observation 
period of 6 months was used to determine 
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 Figure 1  |  Data on epoetin alfa usage in the last quarter of 2005 in the United States, based 
on a sample of 7400 patients. The percentage of total epoetin used according to percentile of 
dose range is an exponential curve. Hyporesponsive patients (  >  150 U / kg of epoetin three times 
weekly) are in the highest quintile of doses (  >  30,000 U / wk). Not surprisingly, they consume more 
than half of all the epoetin used, yet their hemoglobin levels are never greater than those of the 
patients in the lower quintiles. ESA, erythropoiesis-stimulating agent. 
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patients ’ ESA response index and the divi-
sion of responses into quintiles. This 
avoided inclusion of transiently hypo-
responsive patients based on conditions 
not immediately apparent to the clinician. 
Our own experience suggests that a period 
of 6 months is needed to detect hypore-
sponsiveness in about 15 % of the hemo-
dialysis population, who remain 
hyporesponsive for that duration. Th eir 
dose of ESA is markedly higher than that 
of sensitive patients, but because of the 
constraints of the  ‘ target ’ range, the same 
mean Hb is attained. Th e importance of 
detecting this subset resides in the eco-
nomic cost of ESA therapy ( Figure 1 ) and 
in opportunities to avoid harm from 
 “ excessive ” ESA dosing to reach the 
desired Hb target. 
 As important as economics is, the issue 
of risk versus benefit when higher Hb 
levels are targeted may be more impor-
tant. If the findings of an association 
between the relative abundance of onco-
statin M fragments and poor response, 
and between cysteine / histidine-rich 1 and 
good response, can be confi rmed in larger 
cohorts of patients, it may allow us to 
actually conduct the randomized control-
led trials necessary to fi nd the best strat-
egy for managing such poorly responsive 
patients. Certainly, this strategy cannot be 
to increase the ESA dose until the same 
Hb level is reached in poor as in better 
responders — that is, equivalent Hb attain-
ment in all quartiles or quintiles of dose. 
Th e ability to periodically determine the 
responsiveness of the patient can only help 
refi ne the use and prevent the misuse of 
ESAs. 
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 Chronic kidney disease (CKD) strongly 
increases patient risk for cardiovascular 
morbidity and mortality. Th is striking dif-
ference in cardiovascular risk between 
CKD patients and the general population 
is not attributable only to increased expo-
sure to the traditional Framingham Study 
risk factors but in addition depends on a 
number of so-called  ‘ novel, ’ uremia-
related risk factors, among which miner-
alization of blood vessels (vascular 
calcifi cation, an ectopic mineralization) 
takes a prominent position. 1 
 Numerous epidemiologic studies have 
found that vascular calcifi cation in CKD 
patients contributes to the increased 
cardiovascular risk in this population, 
and that hyperphosphatemia and hyper-
calcemic episodes are associated with 
the development of uremia-related vas-
cular calcification. The intimate link 
between disturbances of mineral metab-
olism inherent to impaired renal 
 function and the development of both 
renal osteodystrophy and vascular cal-
cifi cation is now broadly captured under 
the term  ‘ chronic kidney disease –
 mineral and bone disorder. ’ 2 
 Prevention of vascular 
calcification: is pyrophosphate 
therapy a solution ? 
 Veerle P.  Persy 1 and  Marc D.  McKee 2 , 3 
 Pyrophosphate, a ubiquitous small-molecule inhibitor of mineralization 
abundantly present in the extracellular environment, binds to calcium 
and mineral surfaces to inhibit crystal growth. O ’ Neill and colleagues 
show in uremic rats that systemic administration of pyrophosphate 
prevents or reduces uremia-related vascular calcification, without overt 
negative consequences for bone and without calcium pyrophosphate 
deposition disease. These findings prompt further research into the 
potential of pyrophosphate as treatment for vascular calcification in 
chronic kidney disease patients. 
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